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Hermansky-Pudlak syndrome (HPS), consisting of oculocutaneous albinism and a bleeding diathesis due to the
absence of platelet dense granules, displays extensive locus heterogeneity. HPS1 mutations cause HPS-1 disease,
and ADTB3A mutations cause HPS-2 disease, which is known to involve abnormal intracellular vesicle formation.
A third HPS-causing gene, HPS3, was recently identified on the basis of homozygosity mapping of a genetic isolate
of HPS in central Puerto Rico. We now describe the clinical and molecular characteristics of eight patients with
HPS-3 who are of non–Puerto Rican heritage. Five are Ashkenazi Jews; three of these are homozygous for a
1303+1GrA splice-site mutation that causes skipping of exon 5, deleting an RsaI restriction site and decreasing
the amounts of mRNA found on northern blotting. The other two are heterozygous for the 1303+1GrA mutation
and for either an 1831+2TrG or a 2621-2ArG splicing mutation. Of 235 anonymous Ashkenazi Jewish DNA
samples, one was heterozygous for the 1303+1GrA mutation. One seven-year-old boy of German/Swiss extraction
was compound heterozygous for a 2729+1GrC mutation, causing skipping of exon 14, and resulting in a C1329T
missense (R396W), with decreased mRNA production. A 15-year-old Irish/English boy was heterozygous for an
89-bp insertion between exons 16 and 17 resulting from abnormal splicing; his fibroblast HPS3 mRNA is normal
in amount but is increased in size. A 12-year-old girl of Puerto Rican and Italian background has the 3,904-bp
founder deletion from central Puerto Rico on one allele. All eight patients have mild symptoms of HPS; two Jewish
patients had received the diagnosis of ocular, rather than oculocutaneous, albinism. These findings expand the
molecular diagnosis of HPS, provide a screening method for a mutation common among Jews, and suggest that
other patients with mild hypopigmentation and decreased vision should be examined for HPS.
Introduction
Human disorders of hypopigmentation can be divided
into ocular albinism (OA), which is generally X-linked,
and oculocutaneous albinism (OCA), which is usually
inherited in an autosomal recessive fashion (King et al.
2001). OCA1 (MIM 203100) results from deficiency
of tyrosinase, the primary pigment-forming enzyme,
whereas OCA2 (MIM 203200) and “brown OCA” are
results of mutations in the P gene, whose function is
currently under investigation. OCA3 (MIM 203290) re-
sults from mutations in TYRP1, the gene coding for
another melanogenic protein, tyrosinase-related protein
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1 (King et al. 2001). In addition, a variety of syn-
dromes have hypopigmentation as one of their pri-
mary manifestations. These include Chediak-Higashi
syndrome (MIM 214500), which is characterized by
a fatal infectious diathesis and mild bleeding (Introne
et al. 1999), Griscelli syndrome (MIM 214450), which
is characterized by neurological and immunoprolifera-
tive involvement (Griscelli et al. 1978), and Hermansky-
Pudlak syndrome (HPS [MIM 203300]; Hermansky and
Pudlak 1959).
HPS is considered a disorder of the formation of in-
tracellular vesicles, such as the melanosome in mela-
nocytes, the dense body in platelets, and the lysosome
in less-specialized cells (Shotelersuk et al. 1998; Huizing
et al. 2000). This explains both the clinical manifesta-
tions of the disorder (Gahl et al. 1998) and its locus
heterogeneity (Hazelwood et al. 1997; Oh et al. 1998),
because many different gene products are required for
vesicle formation. Patients with HPS exhibit various de-
grees of oculocutaneous albinism, characterized by con-
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genital nystagmus, decreased visual acuity, and hypo-
pigmentation of the skin, hair, and irides (Simon et al.
1982; Summers et al. 1988; Toro et al. 1999; Iwata
et al. 2000). Their platelets lack dense bodies, ac-
counting for the loss of a secondary aggregation re-
sponse and for subsequent bleeding of mucous mem-
branes and soft tissues. The absence of dense granules
in platelets examined by whole-mount electron micros-
copy confirms the diagnosis of HPS (Witkop et al.
1987). Lysosomal involvement in HPS is manifested by
increased accumulation within intracellular vesicles of
ceroid lipofuscin, an amorphous lipid-protein complex
(Witkop et al. 1988). Some patients with HPS develop
granulomatous colitis (Schinella et al. 1980; Mahadeo
et al. 1991) and a fatal pulmonary fibrosis (Garay et
al. 1979; Harmon et al. 1994; Brantly et al. 2000), in
addition to the common manifestations of the disorder
(Gahl et al. 1998).
HPS can be caused by mutations in any one of several
genes, reflecting, in part, the situation in mice, where
15 different genes cause hypopigmentation and platelet
storage-pool deficiency (Swank et al. 1998; Wilson et
al. 2000). In humans, mutations in HPS1, which codes
for a 79.3-kD cytoplasmic protein of unknown function
(Oh et al. 1996), cause HPS-1 disease (MIM 604982).
This disorder is common in northwestern Puerto Rico,
where ∼400 people are homozygous for a 16-bp du-
plication inHPS1 (Witkop et al. 1990). All patients with
HPS-1 are at increased risk of developing pulmonary
fibrosis (Gahl et al. 1998; Brantly et al. 2000).
Mutations in ADTB3A cause human HPS-2 disease
(MIM 603401), which affects only three known indi-
viduals in two families (Shotelersuk et al. 2000; Huizing
et al. 2001b). Patients with HPS-2 have mild oculo
cutaneous albinism, a mild bleeding diathesis, per-
sistent neutropenia, and recurrent childhood infec-
tions. ADTB3A codes for the b3A subunit of adaptor
complex–3 (AP-3), a coat protein that facilitates the
formation of vesicles of lysosomal lineage from the
trans-Golgi network (Simpson et al. 1996; Dell’Angelica
et al. 1997a, 1997b; Simpson et al. 1997). This function
suggests that all types of HPS may result from abnormal
vesicle formation.
Recently, a third HPS-causing gene, HPS3 (MIM
606118), was isolated using a combination of homo-
zygosity mapping, genome database searches, northern
blot analysis, and sequencing applied to patients within
an isolate of HPS from central Puerto Rico (Anikster et
al. 2001). HPS3, on chromosome 3q24, has 17 exons
and a 3,015-bp open reading frame that codes for a
1,004–amino acid protein of unknown function. Cen-
tral Puerto Rican patients with HPS exhibit a founder
effect; all are homozygous for a 3,904-bp deletion re-
moving the first exon of HPS3 and 12 kb of upstream
sequence (Anikster et al. 2001).
We now describe HPS-3 disease andHPS3mutations
in eight non–Puerto Rican patients. HPS-3 disease man-
ifests clinically with mild OCA, absent platelet dense
bodies, and little or no pulmonary disease. We docu-
ment HPS3 mutations that include four splice-site mu-
tations, a C1329T missense mutation, and an 89-bp
insertion, with variable degrees of mRNA expression
on northern blots. In addition, a 13031GrA splice-
site mutation was evident in the homozygous state in
three Ashkenazi Jewish patients and in the heterozygous
state in two other Ashkenazi Jewish patients. Using a
diagnostic assay based on restriction enzymes, we found
this mutation in one of 235 DNA samples from unaf-
fected Ashkenazi Jews. These findings suggest that con-
sideration be given to screening for mutations in HPS3
among patients with OCA—or even those with OAwho
have any history of a bleeding diathesis.
Methods
Patients and Cells
All patients were enrolled in a protocol approved by
the National Institute of Child Health and Human De-
velopment (NICHD) institutional review board to study
the clinical and molecular aspects of HPS. Informed con-
sent was obtained from either the patient or the patient’s
parents. The diagnosis of HPS was based on documen-
tation of OCA (i.e., decreased visual acuity, nystagmus,
and some degree of hypopigmentation relative to family
members) and the absence of platelet dense bodies on
whole-mount electron microscopy (fig. 1). Patient num-
bers correspond to a master file of all NICHD patients
with HPS. Primary cultures of skin fibroblasts, obtained
from a 4-mm punch biopsy, were grown in Dulbecco
modified Eagle medium supplemented with 10% fetal
bovine serum containing 100 U/ml penicillin and 0.1mg/
ml streptomycin.
Electron Microscopy of Platelet Dense Bodies
Platelet-rich plasma, prepared from fresh citrated
blood, was placed on copper grids and treated as de-
scribed elsewhere (Witkop et al. 1987; Hazelwood et al.
1997). The grids were air dried and examined using a
Philips model 301 electron microscope.
PCR Amplification and Sequencing
Standard PCR amplification procedures were used
(Sambrook et al. 1989), with an annealing temperature
of 58C for all primers. Automated sequencing was per-
formed on a Beckman CEQ 2000, using the CEQ Dye
Terminator Cycle Sequencing kit, according to the man-
ufacturer’s protocols.
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Figure 1 Whole-mount electron micrographs of platelet dense bodies. A, Normal platelets showing two to six dense bodies per platelet.
B, Platelets of patient 91, which are devoid of dense bodies. C, Platelets of patient 100, which are totally lacking dense granules.
Northern Blot Analysis
RNA (20 mg), which was isolated from human fi-
broblasts by use of Trizol reagent (Gibco-BRL-Life
Technologies), was electrophoresed on a 1.2% aga-
rose/3% formaldehyde gel and was blotted onto a Ny-
tran nylon membrane (Schleicher and Schuell) in the
presence of 20# sodium chloride (3 M)/sodium cit-
rate (0.3 M). Northern blots of human immune system
and cancer cell lines were purchased from Clontech.
All blots were hybridized and washed, as described
elsewhere (Hazelwood et al. 1997). The probe was a
[32P]-dCTP (DuPont/New England Nuclear) random
primer that was labeled and prepared from human
HPS3 cDNA, using forward primer 5′-TCCTTACCT-
CATGTGGGCTATC-3′ (nt 1179–1200) and reverse
primer 5′-TTCAAGTGAAGTGCAAGCTCGGT-3′ (nt
2341–2319). The same set of filters was also probed
for the b-actin gene.
Screening for HPS-1 and HPS-2
Screening for the northwest Puerto Rican 16-bp du-
plication in the HPS1 gene (GenBank accession number
U65676) was performed by amplifying exon 15 ofHPS1
genomic DNA (forward primer 5′-GATGGTCCACAA-
AGGACGAG-3′ and reverse primer 5′-GCGTGAAGG-
AAGTACGGGCC-3′) and analyzing the products on a
2% agarose gel (Oh et al. 1996; Hazelwood et al. 1997).
Mutation detection for the entire HPS1 gene was per-
formed on genomic DNA by amplifying and sequencing
each exon, as described elsewhere (Bailin et al. 1997).
Screening for defects in ADTB3A (GenBank acces-
sion number U91931) was performed by western blot
analysis of protein extracts of the patients’ fibroblasts
and the use of antibodies (generously provided by M.
Robinson, Cambridge, U.K.) against the b3A subunit
of AP-3 to detect defects in protein expression. Cells
that showed aberrant expression of b3A protein sub-
sequently had their cDNA or genomic DNA sequenced
to detect defects in ADTB3A (Shotelersuk et al. 2000;
Huizing et al. 2001b).
Screening for Mutations in HPS3
A multiplex PCR-amplification assay was performed
on genomic DNA to screen for the common central
Puerto Rican deletion in HPS3 (Anikster et al. 2001).
Primer pairs (nucleotide numbering according to
HPS3 genomic DNA [GenBank accession number
AF375663]) across the deletion (nt 86–106, 5′-GGTG-
TTGTTTAGAGATGCAGA-3′; nt 4639–4616, 5′-GCA-
TAGCCACCAGCTTTTGCAACG-3′) and within the
deletion (nt 2581–2604, 5′-CGTGAACTCCACGTTG-
AGATGTCA-3′; nt 2977-2954, 5′-CGTTCTGACAAT-
TCATCATCTATC-3′) were employed using PCR con-
ditions, as described elsewhere (Anikster et al. 2001).
For patients with no Puerto Rican ancestry, cDNA
was PCR amplified in three overlapping fragments and
was analyzed both on 1% agarose gels and by direct
sequencing. The following HPS3 cDNA (GenBank ac-
cession number AY033141) primer pairs were used:
fragment 1, 5′-CGGACGTCGGGATGGTGCAGC-3′
(nt 130–150) and 5′-GCAAAAATTGTGGCGTGAG-
TAC-3′ (nt 1290–1269); fragment 2, 5′-TCCTTACCTC-
ATGTGGGCTATC-3′ (nt 1179–1200) and 5′-TTCAA-
GTGAAGTGCAAGCTCGGT-3′ (nt 2341–2319); and
fragment 3, 5′-CCTCGGCTGTTGATTCAACAGA-3′
(nt 2177–2298) and 5′-CTCCTCTACTTGTACTTTG-
GCA-3′ (nt 3234–3213). We confirmed mutations found
on cDNA by amplifying the exon in which the mutation
was detected. Primer pairs and conditions for amplifying
each HPS3 exon on genomic DNA have been described
elsewhere (Anikster et al. 2001).
Assays for Specific Mutations
Demonstration of the splice-site mutation resulting in
exon 14 skipping (which was observed in patient 26,
patient 91, and the family of patient 91) involved cDNA
amplification, using forward primer 5′-CCTCGGCT-
GTTGATTCAACAGA-3′ (nt 2177–2298) and reverse
primer 5′-ACCACTACACGGTAAGGTAAGC-3′ (nt
3335–3314). Illustration of the missense mutation in the
other allele of patient 91 was provided by PCR ampli-
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Figure 2 Northern blots demonstrating HPS3 expression. A, Multiple-tissue northern blots hybridized with anHPS3 cDNA (upper panel)
and b-actin (lower panel) probe. The tissue/cell source of RNA is indicated above each lane. pp peripheral; PMLp promyelocytic leukemia;
CML p chronic myelogenous leukemia; LL p lymphoblastic leukemia; Adeno Ca p colorectal adenocarcinoma. B, Northern blots of mRNA
isolated from fibroblasts cultured from patients with HPS who did not have HPS-1 or HPS-2 disease. Patient numbers correspond to a master
list of NICHD patients with HPS.
fication of exon 6, followed by restriction enzyme di-
gestion with DraIII (New England Biolabs) for 3 h at
37C. The insertion in patient 34 was demonstrated by
cDNA amplification, using forward primer 5′-CCTCG-
GCTGTTGATTCAACAG-3′ (nt 2277–2297) and re-
verse primer 5′-TCCTCTACTTGTACTTTGGCA-3′ (nt
3233–3213).
The HPS3 exon 5 skipping, observed in patients of
Ashkenazi Jewish descent, was shown by PCR am-
plification of cDNA, using forward primer 5′-TTGTG-
CATTTCCTGTTGCCCTG-3′ (nt 549–570) and re-
verse primer 5′-CTTGGGTGACTGTCTTCTCTCT-3′
(nt 1532–1511). The presence of the 13031GrA
mutation, in the homozygous or heterozygous state,
was confirmed by amplification of exon 5 genomic DNA
followed by restriction enzyme digestion withRsaI (New
England Biolabs) for 3 h at 37C.
For screening of thismutation inAshkenazi Jewishpop-
ulations, 185 anonymous samples were obtained from the
National Laboratory for the Genetics of Israeli Popula-
tions, through L. Brody of the National Human Genome
Research Institute, and 50 anonymous samples were ob-
tained from patients with Gaucher disease, through E.
Sidransky of the National Institute of Mental Health.
Results
Among our patients with HPS, 31 lacked the 16-bp du-
plication in exon 15 of HPS1, as well as any other mu-
tation in the coding region of HPS1. In addition, these
31 patients expressed a normal contingent of the b3A
subunit of AP-3, as determined by western blotting of
fibroblast extracts. Thus, diagnoses ofHPS-1 disease and
HPS-2 disease were essentially eliminated.
An initial screening for HPS3 mutations involved
northern blot analyses, using RNA obtained from pa-
tients’ cultured fibroblasts. It was previously determined
that heart, brain, placenta, lung, liver, kidney, skeletal
muscle, pancreas, and fibroblasts express HPS3 (An-
ikster et al. 2001), and we further demonstrated that
all other human tissues or cell lines tested, with the
exception of CML line K562, also produce HPS3
mRNA (fig. 2A). The transcript size was ∼4.4 kb, and
no alternatively spliced product was detected on the
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Table 1
Characteristics of Patients with Mutations in HPS3
PATIENT
NUMBER
AGE
(YEARS),
SEX ANCESTRYa
HPS3 MUTATION
VISUAL
ACUITYb
(OD, OS) BLEEDINGc
FVC
(%)d GIe COMMENTSf1 2
26 3, F AJ/Iri-Ger 13031GrA 26212ArG 60, 60 E, Br NA  11q24 Del
91 7, M Ger/Swi 27291GrC C1329T 160, 200 E, Br 75  …
90 12, F PR/Ita Del3904bp Unknown 63, 80 Br 86  Central PR
34 15, M Iri/Eng 3027Ins89bp Unknown 100, 125 E, Br 90  PDA
86 25, F AJ/AJ 13031GrA 18312TrG 160, 100 E, Br, M 96  OA
44 30, F AJ/AJ 13031GrA 13031GrA 125, 100 E, Br, M 84  Transfusion
100 44, F AJ/AJ 13031GrA 13031GrA 100, 160 E, Br 92  OA
89 52, F AJ/AJ 13031GrA 13031GrA 80, 100 Br, M 93  …
a AJ p Ashkenazi Jewish; Iri p Irish; Ger p German; Swi p Swiss; PR p Puerto Rican; Ita p Italian; Eng p English.
b Visual acuity expressed in terms of vision at 20 feet (e.g., 160 indicates 20/160 acuity). OD p right eye; OS p left eye. Patient 26 had
an acuity of 10/30 when tested by use of Allen cards.
c E p epistaxis; Br p bruising; M p menorrhagia.
d FVC p forced vital capacity (expressed as percent of predicted value). Patient 91 may have been too young to provide optimal effort.
e GI p gastrointestinal symptoms of colitis;  p absent.
f Patient 26 has Jacobsen’s syndrome, with an 11q24-11qter deletion. The father of patient 90 is from the central Puerto Rican area where
the 3,904-bp deletion in HPS3 was found. PDA p patent ductus arteriosus. OA p ocular albinism. Patient 44 required a transfusion for
bleeding after wisdom teeth removal.
Figure 3 Multiplex PCR amplification identifying the 3,904-bp
founder deletion of central Puerto Rico. Patient 90 and her father (F)
have the deletion in the heterozygous state, but the mother (M) lacks
the deletion. Mp 100-bp DNA ladder; N1 and N2p normal control
DNA; HPS-3p DNA from a central Puerto Rican patient with HPS-
3 who was homozygous for the deletion.
multiple-tissue northern blots. The expression of HPS3
mRNA in fibroblasts encouraged us to employ northern
blots of fibroblast RNA to screen each of our 31 can-
didate patients for abnormalities in HPS3 expression.
Representative examples illustrate the different amounts
or sizes of HPS3 mRNA produced by the patients’ cul-
tured fibroblasts (fig. 2B). In addition to the expected
4.4-kb HPS3 transcript, a second mRNA band of ∼3
kb hybridized to the HPS3 cDNA probe. This band
could represent an alternatively spliced form of HPS3,
or nonspecific hybridization to the probe. In any event,
this screening procedure pointed to certain patients (26,
34, 44, 86, 89, 90, 91, and 100) later shown to have
mutations in HPS3 (see table 1).
Screening for the Central Puerto Rican Founder
Deletion in HPS3
Genomic DNA from the 31 patients was analyzed for
the presence of the 3,904-bp central Puerto Rican de-
letion in HPS3, using a multiplex PCR assay (Anikster
et al. 2001). No non–Puerto Rican patient exhibited the
deletion. Only one individual (patient 90) was found to
be heterozygous for the deletion. Her father, who was
from central Puerto Rico, also carried the deletion, but
her Italian mother did not (fig. 3). We screened the pa-
tient’s cDNA to identify a mutation in the maternal al-
lele, but the coding region had an entirely normal se-
quence. As expected, northern blot analysis showed a
reduced amount of HPS3 mRNA (fig. 2B).
Other HPS3 Mutations
HPS3 cDNA of all 31 patients was PCR amplified in
three overlapping fragments, and each fragment was an-
alyzed by agarose gel electrophoresis before sequencing.
Fragment 1 was of normal size for all patients, but
cDNA from three Ashkenazi Jews (patients 44, 89, and
100) was not amplified, because—as we later recog-
nized—one of the primers was located in a skipped exon
(see HPS3 Mutations in Patients of Ashkenazi Jewish
Descent section below). Fragment 2 was smaller for one
patient (patient 86); subsequent sequencing showed
skipping of exon 9, changing the reading frame. The
alteration was confirmed by genomic DNA analysis,
which revealed a heterozygous 18312TrG splice-site
mutation.
Fragment 3 displayed an abnormal size when cDNA
was amplified from three patients (91, 26, and 34). Pa-
tients 26 and 91 had a smaller-than-normal fragment 3,
and sequencing showed skipping of exon 14. Genomic
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Figure 4 Mutation analysis in patient 91 and his family. A, PCR amplification of a 1,058-bpHPS3 cDNA fragment showing heterozygous
skipping of exon 14 (with an additional 950-bp band) in patient 91, his two full sisters, and his mother. B, PCR amplification of exon 6 HPS3
genomic DNA (233-bp), followed by restriction enzyme digestion with DraIII. The paternal C1329T mutation introduces a DraIII recognition
site, resulting in 102-bp and 131-bp bands after digestion. Patient 91, his father, and his affected sister carry the C1329T mutation.
DNA analysis of the exon 14 splice sites revealed a het-
erozygous 26212ArGmutation in patient 26, and pa-
tient 91 carried a 27291GrC mutation. PCR analysis
of the family of patient 91 (fig. 4A) indicated that the
mutation was inherited from the mother and transmitted
to the proband’s two full sisters (one affected and one
unaffected). The proband’s unaffected half sister did not
carry the mutation. Sequence analysis of the second allele
of patient 91 revealed a C1329T missense mutation in
exon 6, resulting in an R396W amino acid change and
creation of a recognition site for the restriction enzyme
DraIII. Incubation of PCR-amplified exon 6 fragments
of all family members with DraIII (fig. 4B) indicated
that the father is heterozygous for the C1329Tmutation,
that both of his affected children inherited the mutant
allele, and that his unaffected daughter inherited his nor-
mal allele. Northern blot analysis (fig. 2B) revealed a
decreased amount of HPS3 mRNA in the cultured fi-
broblasts of patient 91.
Patient 34 exhibited a larger-than-normal fragment 3
after cDNA amplification (fig. 5A). Sequencing revealed
an 89-bp insertion in cDNA between nt 3027 and nt
3028, that is, at the splice site between exons 16 and
17 (not shown). The 89-bp insertion appeared to be part
of intron 16 (nt 44102–44191 onHPS3 genomic DNA).
Sequencing of intron 16 revealed a heterozygous GrA
mutation at nt 44101 (fig. 5B). This mutation introduces
a new splice site, resulting in additional exonic material
between exons 16 and 17 (fig. 5C). The 89-bp insertion
in patient 34 results in a change after amino acid 962,
such that 23 new amino acids are translated before a
premature stop is reached at codon 986. This mutation
is present in the heterozygous state in patient 34. In
searching for the second mutation, all 17 exons were
sequenced, but no other mutations were found. No nor-
mal-sized bands of HPS3 mRNA or cDNA were pro-
duced by this patient’s fibroblasts.
HPS3 Mutations in Patients of Ashkenazi Jewish
Descent
Of our 31 candidate patients, 6 were of Ashkenazi
Jewish descent. Five of these (patients 26, 44, 86, 89,
and 100) showed skipping of exon 5 when the appro-
priate portion of their cDNA was amplified (fig. 6A).
Sequencing the intron/exon boundaries of these patients’
genomic DNA revealed a 13031GrA splice-site mu-
tation, present in the homozygous state in patients 44,
100, and 89 and in the heterozygous state in patients
26 and 86. Splice-site mutations present on the second
alleles of patients 26 and 86 had already been identified
(table 1). Amplification of a 908-bpHPS3 cDNA region
revealed a very faint fragment of normal length for the
homozygous patients, and a nearly normal amount of a
normal-sized band in the heterozygous patients, with an
extra, “skipped” band of lesser intensity (fig. 6A). The
fibroblasts of homozygously affected patients expressed
negligible HPS3 mRNA, whereas those of the hetero-
zygous patients showed decreased expression on north-
ern blots (fig. 2B). The 13031GrA splice-sitemutation
was not found in any patients with HPS who were not
of Ashkenazi Jewish descent.
The splice-site mutation deletes an RsaI restriction
site (fig. 6B), and we took advantage of this to estimate
the gene frequency among Ashkenazi Jews. We screened
DNA samples from a total of 235 Ashkenazi Jews
(drawn from a commercial database of 185 unrelated
individuals and a set of 50 patients with Gaucher dis-
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Figure 5 Demonstration of a new splice site in patient 34. A, PCR amplification of a 956-bp cDNA fragment in normal cDNA (N1 and
N2). Amplification reveals an 89-bp insertion. B, Sequencing indicates a heterozygous G44101A mutation in intron 16. C, Schematic drawing
of the 89-bp insertion the patient’s cDNA. Exon 16A is expressed in HPS3 cDNA in a very rare alternative splice form in normal fibroblasts;
however, the G44101C mutation introduces a new consensus splice site that results in insertion of 89-bp of exon 16A in the patient’s cDNA.
Figure 6 Ashkenazi Jewish mutation in HPS3. A, PCR ampli-
fication of a 908-bpHPS3 cDNA fragment, showing homozygous and
heterozygous skipping of exon 5 (714-bp band). B, PCR amplification
of exon 5 genomic DNA (328-bp) followed by RsaI restiction enzyme
digestion. The 13031GrA splice-site mutation deletes an RsaI re-
striction site. Normal genomic DNA is cut into 251-bp, 42-bp, and
35-bp bands; homozygously mutated genomic DNA is cut into 251-
bp and 77-bp bands. Patients 44, 89, and 100 exhibit homozygous
13031GrA mutations. Patients 26 and 86 carry the mutation in the
heterozygous state. Patients 34, 90, and 91 do not have this mutation.
ease). One of the 235 DNA samples contained a single
copy of the mutation.
Clinical Findings
The eight patients with documented HPS3 mutations
were 3–52 years of age. Besides the Ashkenazi Jews from
eastern Europe, affected patients had ancestors of Irish,
English, German, Swiss, and Italian heritage.
Hair and skin color were mildly hypopigmented, in
comparison with other family members, and ranged
from light tan to dark brown (fig. 7A). Iris transillu-
mination was quite variable and correlated somewhat
with the degree of fundus hypopigmentation (fig. 7B).
Visual acuity ranged from 20/63 to 20/200, and all pa-
tients had a history of excessive bruising. Three of the
four adult women reported menorrhagia.
Pulmonary function testing revealed forced vital ca-
pacity values 75%–96% of predicted (normal, 80%–
120%). No patient had a history or any evidence of
granulomatous colitis. Two patients, 86 and 100, carried
the diagnosis of ocular albinism for 25 and 13 years,
respectively. The father of patient 90 was born in the
region of central Puerto Rico where the 3,904-bp foun-
der deletion arose (Anikster et al. 2001).
Discussion
The HPS3 gene, which is responsible for HPS in a
genetic isolate in central Puerto Rico (Anikster et al.
2001), also causes a subtype of HPS among non–
Puerto Rican patients. The common Puerto Rican de-
letion in HPS3—like the founder duplication in HPS1
(Oh et al. 1996; Shotelersuk et al. 1998)—has been iden-
tified only in members of the founder population, in-
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Figure 7 Hypopigmentation of hair, iris, and retina in patients with HPS-3. A, Hair pigmentation in patients of increasing age (see table
1). Color ranges from tan (patient 34) to dark brown (patient 90). Patient 100 tints her hair lighter, but her eyebrows are natural in color. B,
Increasing severity of iris transillumination (top panel) and retinal hypopigmentation (bottom panel) in four patients with HPS-3. The picture
on the left shows the retina of an unaffected control subject. Iris transillumination consists of light transmitted through the iris as a result of
reduced pigment in that tissue. The normal iris remains dark when light is shone through the pupil. In the HPS-3 retinas, patchy hypopigmentation
results from a reduction of pigment epithelium compared with normal retina (left). The degree of fundus hypopigmentation correspondssomewhat
with the extent of iris transillumination.
cluding one Puerto Rican/Italian patient (patient 90)
who inherited the deletion from her father (fig. 3).
Among non–Puerto Rican patients with HPS, however,
other HPS3 mutations give rise to HPS-3 disease.
For example, patient 91 is heterozygous for a splicing
mutation that removes exon 14, consisting of 108 bp.
The 36 amino acids eliminated by this in-frame deletion
are relatively conserved (81%) between humans and
mice (Huizing et al. in press), indicating the importance
of the region. The decrease in HPS3 mRNA (fig. 2B)
suggests that the truncated message is unstable. The
patient’s second mutation consists of an R397W mis-
sense mutation involving an arginine residue that is con-
served from mice to humans but is not part of a specific
signaling or binding domain. PCR amplification and
restriction-site analysis verified that the patients’ two
mutations segregate with HPS-3 disease in the family
(fig. 4).
Patient 34 exhibited an 89-bp insertion of a portion
of intron 16. In attempting to explain how this insertion
arose, we noted that FLJ22704, a cDNA clone coding
for a protein of unknown function, contains a 103-bp
insertion between HPS exons 16 and 17 (called “exon
16A,” nt 44089–44191). We speculate that this clone
represents an alternatively spliced form of HPS3 that is
normally very weakly expressed. (In fact, we were able
to amplify a band from fibroblast cDNA, using a primer
located in exon 16A). In patient 34, a GrA mutation
at nt 44101, within exon 16A, creates a very strong new
splice site, resulting in abundant expression of the 89-
bp insertion. The mutated RNA, which contains 23 new
amino acids and a premature stop at codon 986, ap-
pears stable, because northern blot analysis shows an
mRNA signal slightly larger than the normal 4.4-kb
HPS3 mRNA transcript. It is even possible that trans-
lation of a truncated protein takes place in this patient.
The second mutation of patient 34, a mutation that
is as yet unidentified, is probably severe, because no
normal-sized HPS3 mRNA is expressed by the patient’s
fibroblasts (fig. 2B) and because no normal band ap-
pears on PCR amplification of the cDNA region that
includes exons 16 and 17 (fig. 5A). This suggests a large
deletion or a promoter mutation.
Perhaps our most significant finding is the existence
of a common mutation inHPS3 among patients of Ash-
kenazi Jewish descent. Five of our six Ashkenazi pa-
tients with HPS had mutations in HPS3, and 8 of their
10 alleles carried the 13031GrA splice-site mutation
that removes exon 5. This finding, along with the iden-
tification of one heterozygous carrier of the mutation
among 235 DNA samples from anonymous Ashkenazi
Jews, suggests a founder effect among the Ashkenazim.
HPS is not recognized as a disorder that affects Jews
(Zlotogora et al. 2000), nor has it been listed among
the types of albinism in Israel (Gershoni-Baruch et al.
1994). Certainly, the mildness of the patients’ hypopig-
mentation and bleeding contributes to this situation.
Nevertheless, our findings show a need for heightened
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awareness of the possibility of HPS among Ashkenazi
Jews, particularly those with some degree of albinism
or platelet storage-pool deficiency. For these individuals,
HPS-3 disease and the 13031GrA splicing mutation
in HPS3 should be considered first. Further screening
of Ashkenazi Jewish populations may help to determine
the true frequency of the exon 5 splicing mutation in
this population, and haplotype analysis may allow es-
timation of when the putative founder mutation oc-
curred (Luria and Delbruck 1943; Anikster et al. 2001).
The preponderance of splicing mutations in patients
who have HPS-3 along with drastically reduced mRNA
production suggests that, in general, missensemutations
may not result in a clinically recognizable phenotype.
The HPS-3 disease associated with severe HPS3 mu-
tations is relatively mild, so patients with less-severe
mutations may be indistinguishable from individuals
without HPS3 mutations.
The non–Puerto Rican HPS-3 patients we describe
here enhance our understanding of HPS in other ways.
We know that the HPS3 founder mutation causes rel-
atively mild disease among the few central Puerto Ri-
cans we have examined (Hazelwood et al. 1997; An-
ikster et al. 2001). Clearly, the same is true for other
HPS3 mutations affecting non–Puerto Ricans. Hair hy-
popigmentation (fig. 7A), iris transillumination (fig.
7B), and visual acuity deficits (table 1) were less severe
than those typically seen among patients with HPS-1
(Iwata et al. 2000). In the present study, two individuals
(patients 86 and 100) had such mild skin and hair hy-
popigmentation that they carried the diagnosis of oc-
ular, rather than oculocutaneous, albinism for more
than a decade. The patients’ histories of bleeding were
not impressive; reduction in forced vital capacity was
minimal, if present at all; and no history of colitis was
elicited. This sample of patients with HPS-3 is small,
however, and more and older patients must be examined
to determine whether pulmonary and gastrointestinal
disease will accompany HPS3 mutations.
Strategies for the molecular diagnosis of patients with
HPS are now becoming better defined. Obviously, pa-
tients of northwest Puerto Rican ancestry should be
studied by PCR amplification for the 16-bp duplication
in HPS1 (Oh et al. 1996), and patients from central
Puerto Rico should be analyzed by use of multiplex PCR
for the 3,904-bp deletion inHPS3 (Anikster et al. 2001).
The few patients with HPS who have histories of child-
hood infections or neutropenia can be suspected of hav-
ing HPS-2, with mutations in ADTB3A (Dell’Angelica
et al. 1999; Shotelersuk et al. 2000). Ashkenazi Jewish
individuals, especially those with mild phenotypes,
should be examined using restriction enzyme analysis
of genomic DNA to detect the 13031GrA splice-site
mutation. Other mildly affected patients can be inves-
tigated by amplifying HPS3 cDNA in three overlapping
fragments or, if RNA is not available, by amplifying
and sequencing genomic DNA exon by exon. HPS1
mutations can be pursued in a similar fashion. As an
estimate of the relative likelihood of HPS-1, HPS-2, and
HPS-3 disease, we found 7 patients (6 families) with
HPS1 mutations, 3 patients (2 families) with ADTB3A
mutations, and 8 patients (8 families) with HPS3 mu-
tations among 43 patients with HPS (38 families) not
homozygous for the founder HPS1 orHPS3mutations.
We expect that each HPS-causing gene will provide
unique insights into the cell biology of vesicle formation,
specifically the creation of melanosomes, dense bodies,
and lysosomes from the trans-Golgi network. These or-
ganelles are considered to have a common genesis and
are known to share certain integral membrane proteins
(Shotelersuk et al. 1998; Huizing et al. 2000); they are
also abnormal to various degrees in patients with HPS.
Patients with HPS-2 provide the most-direct evidence
that HPS is a disorder of vesicle formation. In these
individuals, ADTB3A mutations cause defective pro-
duction of b3A, a subunit of the coat protein AP-3. This
heterotetrameric complex mediates the formation of
vesicles, apparently including the melanosome, dense
body, and lysosome. HPS-2 fibroblasts display mistraf-
ficking of the lysosomal membrane protein CD63
through the plasma membrane (Dell’Angelica et al.
1999). HPS-2 melanocytes exhibit misrouting of tyros-
inase, which does not display a normal melanosomal
distribution (Huizing et al. 2001a). The association of
b3A mutations with HPS and with membrane-traffick-
ing defects suggests that the products of HPS1 and
HPS3 also function in vesicle formation, although no
direct evidence to this effect has been forthcoming.
It will be of critical importance to determine whether
the HPS3 gene product interacts with either the HPS1
or the ADTB3A gene product, and these studies are
ongoing.
Because the phenotype of HPS can be extremely mild
with respect to both pigmentation and bleeding, it may
be appropriate to screen for HPS among patients who
have some degree of hypopigmentation. Three separate
HPS-causing genes are known, so molecular studies
could confirm the initial diagnosis. Identification of
patients with a bleeding diathesis among those with
hypopigmentation would assist in prognosis as well as
prophylaxis against serious bleeding episodes or ex-
posure to lung toxins in selected patients. We suggest
that HPS screening be performed by whole-mount elec-
tron microscopy for identification of platelet dense gran-
ules in individuals with oculocutaneous, or even ocular,
albinism. A recent study showed that 35% of a German
albino population had no mutations in either the ty-
rosinase or the P gene (Passmore et al. 1999); these
patients are candidates for having mild HPS.
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